3 Segment information
Key figures by segment
Healthcare | Consumer & Industrial | Others | Total medmix | |||||||||||||
millions of CHF | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | ||||||||
Revenue1) | 171.6 | 176.7 | 276.5 | 307.2 | – | – | 448.0 | 483.9 | ||||||||
Cost of goods sold | –82.6 | –87.0 | –202.2 | –235.8 | –1.3 | –1.4 | –286.1 | –324.2 | ||||||||
Gross profit | 88.9 | 89.7 | 74.2 | 71.4 | –1.3 | –1.4 | 161.9 | 159.7 | ||||||||
Gross profit margin | 51.8% | 50.8% | 26.9% | 23.3% | n/a | n/a | 36.1% | 33.0% | ||||||||
1)Revenue from external customers.
Information about reportable segments
Operating segments are determined based on the reports reviewed by the Board of Directors (BoD, chief operating decision maker) that are used to measure performance, make strategic decisions and allocate resources to the segments. The business is managed based on segments, and the reportable segments have been identified as disclosed below.
The BoD evaluates the performance of the two business segments based on revenue, cost of goods sold, gross profit and gross profit margin. Accordingly, the group reports these metrics by segment for 2025 and 2024. In the prior year, segment performance was assessed using alternative performance measures (APMs)–segment cost of goods sold, segment gross profit and segment gross profit margin–which are no longer relevant from 2025 onwards. As these measures are no longer used for internal decision‑making, they are not presented for external reporting purposes.
Revenue from external customers reported to the BoD is measured in a manner consistent with that in the income statement. There is no significant revenue between the segments. No individual customer represents a significant portion of the group’s revenue.
Healthcare
Through its well-known brands Haselmeier, Medmix, Mixpac and Transcodent, the Healthcare segment specializes in the design and production of innovative, high-precision delivery devices and services within the drug delivery, surgery and dental markets. Products include injection pens for subcutaneous delivery of drugs, surgical delivery devices focusing on trauma bone repair and wound-healing tissue treatment, and mixing, filling and delivery device systems for the dental consumable industry.
The segment’s IP-protected solutions make customers’ products precise, safe, unique and more sustainable, leveraging the business’s expertise in drug delivery, plastic-injection technology, molding and two-component mixing.
Consumer & Industrial
Through its well-known brands Mixpac, Qiaoyi, MK, Cox and Geka, the Consumer & Industrial segment specializes in the design and production of innovative, high-precision delivery devices and services within the Industry business unit, such as adhesives used in construction, electronics, automotive, aerospace and various industries, and consumer markets such as beauty and other microbrush applications. Products include hand-held mixing and dispensing delivery devices for two-component adhesives and sealants, mixing tips, cartridges, high-precision makeup applicators and microbrushes.
The segment’s IP-protected solutions make customers’ products precise, safe, unique and more sustainable, leveraging the business’s expertise in plastic injection molding, two-component mixing, fluid handling, material design and microbrushes.
Others
Certain expenses related to the Corporate Center are not attributable to a particular segment and are reviewed as a whole across the group.
Regional information
The allocation of assets is based on their geographical location. Non-current assets exclude non-current financial assets (other than investments in associates), deferred income tax assets and defined benefit assets. The allocation of revenue from external customers is based on the ship-to location defined by the group’s customer, which does not necessarily correspond with the location of the end-customer.
Non-current assets by region
millions of CHF | 2025 | 2024 | ||
Europe, the Middle East and Africa | 521.4 | 526.8 | ||
– thereof Germany | 260.0 | 274.4 | ||
– thereof Switzerland | 197.0 | 187.1 | ||
– thereof Spain | 43.9 | 43.0 | ||
– thereof United Kingdom | 14.4 | 17.3 | ||
Americas | 68.9 | 67.7 | ||
– thereof USA | 66.4 | 65.9 | ||
Asia-Pacific | 49.0 | 56.5 | ||
– thereof China | 48.2 | 55.6 | ||
Total non-current assets | 639.3 | 651.0 |
Revenue by region
millions of CHF | 2025 | 2024 | ||
Europe, the Middle East and Africa | 265.6 | 285.4 | ||
– thereof Germany | 101.1 | 108.2 | ||
– thereof Italy | 42.5 | 42.7 | ||
– thereof France | 23.1 | 26.0 | ||
– thereof United Kingdom | 18.7 | 25.4 | ||
– thereof Switzerland | 17.9 | 19.4 | ||
Americas | 129.0 | 140.5 | ||
– thereof USA | 112.2 | 120.0 | ||
Asia-Pacific | 53.4 | 58.0 | ||
– thereof China | 23.4 | 24.7 | ||
– thereof Japan | 13.1 | 13.0 | ||
Total revenue | 448.0 | 483.9 |
Business unit information
The following table shows the allocation of revenue from external customers by business unit:
Revenue by business unit
millions of CHF | 2025 | 2024 | ||
Dental | 120.1 | 115.6 | ||
Drug Delivery | 34.2 | 43.4 | ||
Surgery | 17.3 | 17.7 | ||
Total Healthcare | 171.6 | 176.7 | ||
Industry | 124.3 | 126.6 | ||
Beauty | 152.1 | 180.6 | ||
Total Consumer & Industrial | 276.5 | 307.2 | ||
Total revenue | 448.0 | 483.9 |